See more : M3-Brigade Acquisition II Corp. (MBAC-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Fresh Tracks Therapeutics, Inc. (FRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresh Tracks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wärtsilä Oyj Abp (WRT1V.HE) Income Statement Analysis – Financial Results
- Radius Health, Inc. (RDUS) Income Statement Analysis – Financial Results
- Epiphany Technology Acquisition Corp. (EPHYW) Income Statement Analysis – Financial Results
- Satsuma Pharmaceuticals, Inc. (STSA) Income Statement Analysis – Financial Results
- Waste Management, Inc. (WM) Income Statement Analysis – Financial Results
Fresh Tracks Therapeutics, Inc. (FRTX)
About Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.01M | 6.94M | 404.00K | 1.82M | 7.92M | 1.62M | 13.82M | 14.53M | 20.95M | 15.22M | 7.72M | 17.52M | 30.02M | 8.71M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 7.62M | 10.70M | 5.90M | 7.80M | 6.70M | 6.30M | 5.50M | 6.00M | 3.60M | 2.40M | 1.80M |
| Cost of Revenue | 0.00 | 14.04M | 28.23M | 11.22M | 20.21M | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 0.00 | 10.27M | 11.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.00M | -900.00K | -900.00K | -600.00K | -500.00K | -500.00K | 5.70M | 4.00M | 3.00M | 2.20M |
| Gross Profit | 8.01M | -7.10M | -27.83M | -9.39M | -12.30M | 186.00K | 7.34M | 8.24M | 10.02M | 4.39M | -4.98M | 17.52M | 19.75M | -2.73M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 8.82M | 11.70M | 6.80M | 8.70M | 7.30M | 6.80M | 6.00M | 300.00K | -400.00K | -600.00K | -400.00K |
| Gross Profit Ratio | 100.00% | -102.26% | -6,887.87% | -515.59% | -155.32% | 11.47% | 53.12% | 56.71% | 47.84% | 28.87% | -64.52% | 100.00% | 65.80% | -31.28% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.75% | 109.35% | 115.25% | 111.54% | 108.96% | 107.94% | 109.09% | 5.00% | -11.11% | -25.00% | -22.22% |
| Research & Development | 3.18M | 14.04M | 28.23M | 11.22M | 20.21M | 12.33M | 14.39M | 10.36M | 11.06M | 11.47M | 14.56M | 17.34M | 17.98M | 19.69M | 23.45M | 25.53M | 22.93M | 18.51M | 17.77M | 31.18M | 26.78M | 26.37M | 22.07M | 18.51M | 15.30M | 12.10M | 11.90M | 11.30M | 9.00M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 0.00 | 8.80M | 7.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 13.06M | 0.00 | 0.00 | 10.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 9.60M | 8.80M | 17.82M | 19.77M | 22.84M | 22.64M | 19.88M | 8.51M | 6.92M | 8.06M | 6.52M | 5.27M | 4.40M | 3.60M | 3.70M | 3.20M | 2.90M | 2.60M | 2.00M | 1.40M | 1.10M | 800.00K |
| Other Expenses | 0.00 | 441.00K | 839.00K | 0.00 | 0.00 | -1.44M | -6.48M | -6.29M | -10.93M | -10.82M | -12.70M | -13.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 482.22K | 4.20M | 0.00 | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| Operating Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 27.57M | 28.49M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 24.98M | 20.70M | 16.60M | 16.50M | 15.10M | 12.40M | 11.40M | 2.40M | 1.80M | 1.70M | 1.40M |
| Cost & Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 37.84M | 39.93M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 23.78M | 19.70M | 15.70M | 15.60M | 14.50M | 11.90M | 10.90M | 8.10M | 5.80M | 4.70M | 3.60M |
| Interest Income | 0.00 | 9.00K | 69.00K | 63.00K | 1.94M | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 2.21M | 2.07M | 3.98M | 8.29M | 9.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.00K | 9.00K | 69.00K | 0.00 | 2.10M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 21.00K | 96.00K | 272.00K | 533.00K | 795.00K | 412.82K | 288.25K | 296.58K | 204.60K | 0.00 | 200.00K | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 100.00K | 100.00K |
| Depreciation & Amortization | 41.00K | 30.00K | 22.00K | 10.00K | 28.00K | 49.00K | 793.00K | 1.12M | 1.16M | 1.66M | 2.21M | 1.98M | 2.30M | 2.81M | 2.63M | 2.87M | 3.26M | 3.28M | 3.59M | 3.64M | 3.54M | 2.74M | 1.88M | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| EBITDA | -5.65M | -21.06M | -39.38M | -20.90M | -24.47M | -19.50M | -12.59M | -8.06M | -8.25M | -14.96M | -29.14M | -21.11M | -5.32M | -28.41M | -25.93M | -34.48M | -37.00M | -23.13M | -22.06M | -21.51M | -22.56M | -28.89M | -15.35M | -14.96M | -8.00M | -8.90M | -6.90M | -7.20M | -5.10M | -4.90M | -1.70M | -1.80M | -1.70M | -1.20M |
| EBITDA Ratio | -70.55% | -303.80% | -9,961.39% | -1,151.26% | -309.06% | -1,420.35% | -99.95% | -64.56% | -40.15% | -110.14% | -407.70% | -136.81% | -27.85% | -326.10% | -204.85% | -439.20% | -752.21% | -180.97% | -183.76% | -147.86% | -273.30% | -352.37% | -135.02% | -196.31% | -74.77% | -191.53% | -119.23% | -149.25% | -107.94% | -110.91% | -43.33% | -58.33% | -75.00% | -77.78% |
| Operating Income | -6.36M | -21.53M | -40.24M | -20.98M | -24.47M | -19.65M | -13.39M | -9.18M | -9.40M | -16.63M | -31.35M | -23.43M | -7.82M | -31.22M | -28.59M | -37.34M | -40.26M | -26.42M | -25.65M | -25.14M | -26.10M | -31.63M | -17.23M | -16.16M | -9.00M | -9.80M | -7.80M | -7.80M | -5.60M | -5.40M | -2.10M | -2.20M | -2.30M | -1.80M |
| Operating Income Ratio | -79.44% | -310.15% | -9,961.39% | -1,151.26% | -309.06% | -1,211.22% | -96.87% | -63.15% | -44.89% | -109.26% | -406.22% | -133.76% | -26.06% | -358.34% | -225.34% | -469.37% | -730.44% | -179.22% | -213.70% | -172.86% | -323.12% | -451.36% | -151.59% | -212.06% | -84.11% | -166.10% | -100.00% | -116.42% | -88.89% | -98.18% | -35.00% | -61.11% | -95.83% | -100.00% |
| Total Other Income/Expenses | 666.00K | 432.00K | 770.00K | 63.00K | 591.00K | 3.39M | 426.00K | 204.00K | 166.00K | 134.00K | 114.00K | 534.00K | 539.00K | 830.00K | 28.00K | 468.00K | 4.46M | 3.54M | 0.00 | 0.00 | -481.56K | -4.20M | 0.00 | 0.00 | 0.00 | 2.40M | 2.40M | 2.80M | 1.70M | 1.20M | 900.00K | 300.00K | 100.00K | 200.00K |
| Income Before Tax | -5.69M | -21.10M | -39.47M | -20.91M | -23.88M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.88M | -35.80M | -22.88M | 0.00 | 0.00 | -26.59M | -35.83M | 0.00 | 0.00 | 0.00 | -7.40M | -5.40M | -5.00M | -3.90M | -4.20M | -1.20M | -1.90M | -2.20M | -1.60M |
| Income Before Tax Ratio | -71.12% | -303.93% | -9,770.79% | -1,147.80% | -301.59% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.10% | -463.49% | -649.46% | -155.20% | 0.00% | 0.00% | -329.09% | -511.30% | 0.00% | 0.00% | 0.00% | -125.42% | -69.23% | -74.63% | -61.90% | -76.36% | -20.00% | -52.78% | -91.67% | -88.89% |
| Income Tax Expense | 0.00 | -441.00K | 47.00K | -10.00K | 2.07M | 4.48M | -1.22M | -1.32M | -166.00K | -1.80M | -2.33M | -2.52M | -2.84M | 0.00 | -28.00K | -447.00K | -4.37M | -3.27M | -1.29M | -1.41M | -1.65M | -3.70M | -7.99M | -7.64M | -2.10M | -2.30M | -2.20M | -2.70M | -1.60M | -1.00M | -700.00K | -200.00K | 0.00 | -100.00K |
| Net Income | -5.69M | -20.66M | -39.52M | -20.90M | -25.95M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.90M | -35.89M | -23.15M | -24.36M | -23.73M | -24.45M | -27.93M | -9.24M | -8.52M | -6.90M | -7.50M | -5.60M | -5.10M | -4.00M | -4.40M | -1.40M | -2.00M | -2.30M | -1.70M |
| Net Income Ratio | -71.12% | -297.58% | -9,782.43% | -1,147.26% | -327.71% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.11% | -463.75% | -651.20% | -157.04% | -202.92% | -163.17% | -302.65% | -398.62% | -81.29% | -111.77% | -64.49% | -127.12% | -71.79% | -76.12% | -63.49% | -80.00% | -23.33% | -55.56% | -95.83% | -94.44% |
| EPS | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.50K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| EPS Diluted | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.49K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| Weighted Avg Shares Out | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.02K | 4.92K | 4.88K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
| Weighted Avg Shares Out (Dil) | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.04K | 4.93K | 4.89K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution Company intends to make cash...
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc.
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value
Why Is Fresh Tracks Therapeutics (FRTX) Stock Up 92% Today?
Fresh Tracks Therapeutics (NASDAQ: FRTX ) stock is heading higher on Wednesday after announcing positive results from a Phase 1 clinical trial. That clinical trial covers the use of FRTX-02 to restore immunity balance.
Best Penny Stocks To Buy? 4 To Watch In January 2023
4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call Transcript
Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Garth Russell - LifeSci Advisors Robert Brown - CEO Monica Luchi - Chief Medical Officer Albert Marchio - CFO Conference Call...
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
Fresh Tracks Therapeutics (FRTX) delivered earnings and revenue surprises of -9.52% and 56.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment...
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript
Brickell Biotech, Inc. (NASDAQ:BBI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Monica Luchi - Chief Medical Officer Albert Marchio - Chief...
Source: https://incomestatements.info
Category: Stock Reports